Trump Administration Freezes Federal Child Care Funds Over Fraud Concerns 
Astronomers have discovered another puzzling interstellar object − this third one is big, bright and fast 
China Ends Contraceptive Tax Exemption to Boost Birth Rates 
Novo Nordisk Launches Once-Daily Wegovy Pill in U.S. at Competitive Pricing 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence 
Ancient Mars may have had a carbon cycle − a new study suggests the red planet may have once been warmer, wetter and more favorable for life 
China to Tighten Crude Steel Output Controls and Export Regulation Through 2030 
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
U.S. Appeals Court Allows Trump Administration to Enforce Medicaid Funding Ban on Planned Parenthood 
Senate Sets December 8 Vote on Trump’s NASA Nominee Jared Isaacman 
The U.S. Food and Drug Administration (FDA) has removed the Risk Evaluation and Mitigation Strategies (REMS) requirement for all currently approved CAR-T cell therapies, a move expected to improve patient access to these advanced cancer treatments.
CAR-T cell therapy, a form of gene therapy used to treat blood cancers such as leukemia, lymphoma, and multiple myeloma, involves reprogramming a patient’s T-cells to attack cancer cells. Despite serious side effects, including cytokine release syndrome and neurological toxicities, the FDA concluded that existing labeling and boxed warnings are sufficient to communicate these risks without the need for REMS.
This regulatory update affects therapies including Bristol-Myers Squibb’s Breyanzi and Abecma (developed with 2seventy bio), Johnson & Johnson’s Carvykti (with Legend Biotech), Novartis’ Kymriah, and Gilead’s Tecartus and Yescarta. Gilead confirmed label updates to reflect the FDA’s decision, stating it would ease the burden on healthcare providers and expand access to potentially curative treatments.
Bristol-Myers Squibb echoed this sentiment, emphasizing its commitment to breaking down barriers to CAR-T access. These therapies have been a breakthrough in oncology, offering new hope for patients with few alternatives.
In January 2024, the FDA had mandated additional safety warnings for CAR-T drugs following reports of secondary T-cell malignancies, including leukemia and lymphoma. Despite these risks, the agency now believes they can be effectively managed through existing safety measures.
With this change, the FDA aims to streamline access to CAR-T therapies while maintaining patient safety, reinforcing its support for innovation in personalized cancer treatment. This decision marks a significant regulatory shift that could accelerate the adoption of CAR-T across oncology care.
